50 results on '"Duangchinda, Thaneeya"'
Search Results
2. The alteration of NK cells phenotypes related to the functions and dengue disease outcomes
3. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
4. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
5. Immunogenicity and durability against micron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
6. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus
7. Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection.
8. Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques
9. Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study
10. Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody
11. Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus
12. Study of dengue virus specific T lymphocytes in Thai populations
13. Neutralizing antibodies against omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity
14. Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years
15. Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response
16. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
17. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
18. Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
19. Effects of boosted mRNA and adenoviral‐vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination
20. Safety and Immunogenicity of Intradermal Administration of Fractional Dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as Primary Series Vaccination
21. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus
22. Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination
23. Development of a Singleplex Real-Time Reverse Transcriptase PCR Assay for Pan-Dengue Virus Detection and Quantification
24. Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination
25. Omicron BA.1, BA.2 and COVID-19 Booster Vaccination
26. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
27. COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
28. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF
29. Potent programmable antiviral against dengue virus in primary human cells by Cas13b RNP with short spacer and delivery by VLP
30. Cross-reacting antibodies enhance dengue virus infection in humans
31. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever
32. Multi-color fluorescent reporter dengue viruses with improved stability for analysis of a multi-virus infection
33. Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity1
34. Erratum: Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus
35. Enhancing cross-reactive anti-prM dominates the human antibody response in dengue infection
36. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus
37. Invariant NKT Cell Response to Dengue Virus Infection in Human
38. Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+T cell response
39. Structural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-Reactivity
40. The development of a novel serotyping-NS1-ELISA to identify serotypes of dengue virus
41. A Complex Interplay among Virus, Dendritic Cells, T Cells, and Cytokines in Dengue Virus Infections
42. T Cell Responses in Dengue Hemorrhagic Fever: Are Cross-Reactive T Cells Suboptimal?
43. Production of anti-dengue NS1 monoclonal antibodies by DNA immunization
44. Construction of infectious dengue 2 virus cDNA clones using high copy number plasmid
45. Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.
46. An Engineered N-Glycosylated Dengue Envelope Protein Domain III Facilitates Epitope-Directed Selection of Potently Neutralizing and Minimally Enhancing Antibodies.
47. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3-4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination.
48. Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.
49. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac ® , ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination.
50. Potent programmable antiviral against dengue virus in primary human cells by Cas13b RNP with short spacer and delivery by VLP.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.